SURGICAL TREATMENT OF CARDIAC ARRHYTHMIAS

$563,152R01FY2014HLNIH

Washington University, Saint Louis MO

Investigators

Linked publications, trials & patents

Paper 38629291 Paper 38204688 Paper 37555041 Paper 36642681 Paper 34045056 Paper 34041815 Paper 33965223 Paper 33662312 Paper 33653608 Paper 32563577 Paper 32522634 Paper 32389465 Paper 31077661 Paper 30928552 Paper 30516572 Paper 30336917 Paper 30138243 Paper 29232302 Paper 29056264 Paper 28838486 Paper 28549027 Paper 28390766 Paper 28274566 Paper 28187972 Paper 28007240 Paper 27930603 Paper 27756468 Paper 27635475 Paper 27596917 Paper 26968668 Paper 26889882 Paper 26777943 Paper 26507426 Paper 26432719 Paper 26432717 Paper 26209496 Paper 25510286 Paper 25443237 Paper 25389650 Paper 25048635 Paper 24523494 Paper 24516798 Paper 24484804 Paper 24145972 Paper 23998785 Paper 23995989 Paper 23916806 Paper 23823731 Paper 23642681 Paper 23422803 Paper 23422802 Paper 22995722 Paper 22953591 Paper 22818126 Paper 22549742 Paper 22505644 Paper 22323899 Paper 22305553 Paper 22305055 Paper 22095640 Paper 21978962 Paper 21596173 Paper 21340516 Paper 21168019 Paper 21057605 Paper 20946995 Paper 20855661 Paper 20473355 Paper 20434173 Paper 20122702 Paper 19959142 Paper 19782848 Paper 19777083 Paper 19740492 Paper 19631907 Paper 19026819 Paper 19026812 Paper 18774106 Paper 18374777 Paper 18374771 Paper 18175210 Paper 17765626 Paper 17462374 Paper 17403456 Paper 17043619 Paper 17000297 Paper 16998367 Paper 16920139 Paper 16872962 Paper 16159868 Paper 16099735 Paper 15927979 Paper 15632831 Paper 15511454 Paper 15511453 Paper 15364857 Paper 14688721 Paper 14688693 Paper 12963212 Patent 7918847

Abstract

DESCRIPTION (provided by applicant): The highest incidence of atrial fibrillation (AF) in patients referred for cardiac surgery is seen in patients with mitral valve (MV) disease. Approximately 30% of patients referred for MV surgery have AF. Two to 2.5 million Americans suffer from MV disease and this prevalence is expected to double in the next 20 years. The worldwide burden of MV disease is even greater, and it is the most common underlying etiology of AF in the developing world. The most common underlying pathology is mitral regurgitation (MR).The purpose of this proposed project is to characterize the chronic structural, electrical, and mechanical remodeling of the atria in a novel reversible chronic animal model of mitral regurgitation (MR), with and without AF, to optimize and improve the surgical treatment of patients with MR and Aft realize this goal, our laboratory has created a novel model to look at left atrial volume overload that is physiologically similar to MR and has the advantage of being reversible, obviating the confounding effects of corrective surgery. A shunt is made between the pulmonary veins and the left ventricle (LV). The specific aims are: Aim 1. To characterize the electrical, structural, and mechanical remodeling in an acute and chronic canine model of MR and to determine if eliminating the MR reverses these changes. Aim 2. A. To determine the time course of the inducibility of AF, after the onset of MR and determine the combined effects of MR and AF on the substrates responsible for the initiation and maintenance of AF. B. Determine the effect of eliminating the MR on these substrates. Aim 3. To characterize the electrical and structural remodeling in patients with MR, and to correlate these data with the experimental animal model. Successful completion of these aims will help elucidate the evolution of the substrate for AF in patients with MR. Because these are the most common AF patients who present for surgery, understanding the time course and interaction of the mechanically induced electrical remodeling, as well as its reversibility, will help provide a rationale for determining he appropriate timing of surgery and which patients require AF ablation in addition to their MV surgery. In those patients needing AF ablation, these studies may suggest a more rational ablation strategy.

View original record on NIH RePORTER →